Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/752| TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib | |
| Wu, D Yang, X | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles. | |
| Journal of Microbiology, Immunology, and Infection / Wei Mian Yu Gan Ran za Zhi | |
| 2020 | |
| Preimpreso | |
| https://coronavirus.1science.com/item/35f6314cc85c644b485331ed6b4a25c439106027 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 101921.pdf | 266.48 kB | Adobe PDF | Visualizar/Abrir |